News | July 03, 2023
Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
The new range of HDPE bottles is compliant with US FDA, EU regulations and Chinese DMF registration for use in dry pharmaceutical applications
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
Pfizer is likely to show GSK significant competition
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
Subscribe To Our Newsletter & Stay Updated
